Key result
Direct renin inhibitors cut plasma renin activity ~74% in diabetic nephropathy despite typical low-renin states.
Why the study?
Renin inhibition has been suggested for diabetic nephropathy, but scientific evidence and proof-of-concept studies supporting the use of direct renin inhibitors remain scant.
Do direct renin inhibitors reduce plasma renin activity and improve renal outcomes in patients with diabetic nephropathy?
Systematic Review (n=370)
Do direct renin inhibitors reduce plasma renin activity and improve renal outcomes in patients with diabetic nephropathy?
Evidence for direct renin inhibition in diabetic nephropathy is limited, and because diabetes is often a low-renin state, plasma renin activity may be a necessary biomarker to identify patients who would actually benefit from this therapy.
Answers are grounded in this paper and cite their sources.
Direct renin inhibitors lower PRA in diabetic nephropathy but limited data warrant caution; leaves open PRA as a biomarker for renal benefit.
The purpose of this systematic review was to investigate the scientific evidence to support the use of direct renin inhibitors (DRIs) in diabetic nephropathy (DN). MEDLINE was searched for articles reported until 2018. A standardized dataset was extracted from articles describing the effects of DRIs on plasma renin activity (PRA) in DN. A total of 3 clinical articles studying PRA as an outcome measure for DRIs use in DN were identified. These clinical studies were randomized controlled trials (RCTs): 1 double-blind crossover, 1 post hoc of a double-blind and placebo-controlled study, and 1 open-label and parallel-controlled study. Two studies reported a significant decrease of albuminuria associated with PRA reduction. One study had a DRI as monotherapy compared to placebo, and 2 studies had DRI as add-in to an ARB. Of 10393 patients with DN enrolled in 5 studies with DRI, 370 (3.6%) patients had PRA measured. Only one preclinical study was identified determined PRA when investigating the effects of aliskiren in DN. Moreover, most of observational preclinical and clinical studies identified report on a low PRA or hyporeninemic hypoaldosteronism in DM. Renin inhibition has been suggested for DN, but proof of concept studies for this are scant. A small number of clinical and preclinical studies assessed the PRA effects of DRIs in DN. For a more successful translational research for DRIs, specific patient population responsive to the treatment should be identified and PRA may remain a biomarker of choice for patient stratification.
No takes yet. Share an insight, caveat, or question.
Massolini et al. (2020) conducted a systematic review in Diabetic Nephropathy (n=370). Direct renin inhibitors (aliskiren) vs. Placebo or standard therapy was evaluated on Plasma renin activity (PRA). Direct renin inhibitors reduced plasma renin activity by 71-77% in patients with diabetic nephropathy, though proof-of-concept studies are scant and diabetes is generally associated with a low-renin state.
Synapse has enriched 10 related papers. Consider them for comparative context: